4 Healthcare Stock Stories For Tuesday Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Cleveland BioLabs (NASDAQ:CBLI): Closing price $1.58

Cleveland BioLabs and Incuron, a joint venture between the former and Bioprocess Capital Ventures, on Tuesday reported the receipt of a Notice of Allowance from the United States Patent and Trademark Office for the Curaxin Patent Application Number 12/993,018, titled Inducing Cell Death by Inhibiting Adaptive Heat Shock Response. This patent was recently also issued in the Russian Federation. Curaxins include the carbazole and CBL0102 CBL0137, which is a quinacrine.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CBLI

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Closing price $26.74

On Tuesday, Ligand said that its partner Rib-X Pharmaceuticals has begun a Phase 3 clinical trial of a Captisol-enabled” intravenous (IV) formulation of delafloxacin for the first-line treatment of acute bacterial skin and skin structure infections, including infections caused by MRSA. Through the terms of a license and supply agreement, Ligand has earned a $500,000 milestone payment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LGND

Insmed Incorporated (NASDAQ: INSM): Closing price $9.14

Insmed announced Tuesday that the European Patent Office will grant European Union Patent No. 1909759 for Arikace (liposomal amikacin for inhalation). Once granted, the composition of matter patent gives exclusivity in any of the European Patent Office’s member states where Insmed  wishes to file at least through July 19, 2026. The firm’s liposomal amikacin for inhalation is in clinical development so as to treat cystic fibrosis patients suffering from Pseudomonas aeruginosa lung infections and patients with nontuberculous mycobacteria lung infections. Insmed is a biopharmaceutical firm focused on the development  and commercialization of an inhaled anti-infective to treat patients struggling with serious lung diseases in orphan indications that are often life-threatening.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

INSM

Rockwell Medical (NASDAQ:RMTI): Closing price $3.59

Rockwell announced Tuesday its intention to offer shares of its common stock in an underwritten public offering. The company also intends to alow the underwriters a 30-day option to buy as much as an additional 15 percent of the shares offered in the public offering to cover over-any allotments.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RMTI

Investing Insights: Does Dendreon Still Have Potential?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business